Michael A. Weller
Expertise in
23
conditions

Dr. Michael A. Weller

Radiation Oncology
6780 Mayfield Rd, 
Mayfield Heights, OH 
On Staff At
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Expertise in
23
conditions
6780 Mayfield Rd, 
Mayfield Heights, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Michael Weller is a Radiation Oncologist in Mayfield Heights, Ohio. Dr. Weller is highly rated in 23 conditions, according to our data. His top areas of expertise are Glioma, Glioblastoma, Gliomatosis Cerebri, Thrombectomy, and Gamma Knife Radiosurgery.

His clinical research consists of co-authoring 700 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Radiation Oncology
Licenses
Radiology in OH
Hospital Affiliations
Cleveland Clinic
Hillcrest Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

Hillcrest Hospital
6780 Mayfield Rd, Mayfield Heights, OH 44124

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM
GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM
Enrollment Status: Recruiting
Publish Date: May 25, 2025
Intervention Type: Drug, Radiation, Biological
Study Drugs: Temozolomide, Lomustine, Regorafenib, Paxalisib, VAL-083
Study Phase: Phase 2/Phase 3
A Multicenter, Open-Label Study With a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy
A Multicenter, Open-Label Study With a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy
Enrollment Status: Active_not_recruiting
Publish Date: May 04, 2025
Intervention Type: Drug
Study Drugs: Berubicin, Lomustine
Study Phase: Phase 2
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Enrollment Status: Active_not_recruiting
Publish Date: August 02, 2024
Intervention Type: Drug, Radiation
Study Drugs: Concomitant Temozolomide (TMZ), Procarbazine, Adjuvant Temozolomide (TMZ), CCNU, Vincristine
Study Phase: Phase 3
Molecular Genetic, Host-derived and Clinical Determinants of Long-term Survival in Glioblastoma
Molecular Genetic, Host-derived and Clinical Determinants of Long-term Survival in Glioblastoma
Enrollment Status: Completed
Publish Date: March 08, 2024
Intervention Type: Procedure
Study of TG02 in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma: A Phase Ib Study
Study of TG02 in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma: A Phase Ib Study
Enrollment Status: Completed
Publish Date: May 31, 2022
Intervention Type: Radiation, Drug
Study Drugs: TG02, Temozolomide
Study Phase: Phase 1
IDH Mutated 1p/19q Intact Lower Grade Glioma Following Resection: Wait Or Treat? IWOT - a Phase III Study
IDH Mutated 1p/19q Intact Lower Grade Glioma Following Resection: Wait Or Treat? IWOT - a Phase III Study
Enrollment Status: Terminated
Publish Date: February 01, 2022
Intervention Type: Radiation, Drug, Procedure
Study Drug: Temozolomide
Study Phase: Phase 3
An International, Randomized, Open-label Phase I/II Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Adult Patients With Recurrent or Refractory Medulloblastomas Presenting an Activation of the Sonic Hedgehog (SHH) Pathway
An International, Randomized, Open-label Phase I/II Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Adult Patients With Recurrent or Refractory Medulloblastomas Presenting an Activation of the Sonic Hedgehog (SHH) Pathway
Enrollment Status: Terminated
Publish Date: May 21, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 6 Less Clinical Trials

700 Total Publications

Author Correction: RANO criteria for response assessment of brain metastases based on amino acid PET imaging.
Author Correction: RANO criteria for response assessment of brain metastases based on amino acid PET imaging.
Journal: Nature medicine
Published: June 09, 2025
Similar Doctors
Expertise in
41
conditions
Dr. Samuel T. Chao
Radiation Oncology
Expertise in
41
conditions
Dr. Samuel T. Chao
Radiation Oncology

Cleveland Clinic Main Campus

9500 Euclid Ave, 
Cleveland, OH 
 (9.7 mi)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Samuel Chao is a Radiation Oncologist in Cleveland, Ohio. Dr. Chao is highly rated in 41 conditions, according to our data. His top areas of expertise are Brain Tumor, Astrocytoma, Glioma, Metastatic Brain Tumor, and Gamma Knife Radiosurgery. Dr. Chao is currently accepting new patients.

Expertise in
35
conditions
Dr. John H. Suh
Radiation Oncology
Expertise in
35
conditions
Dr. John H. Suh
Radiation Oncology

Cleveland Clinic Main Campus

9500 Euclid Avenue, 
Cleveland, OH 
 (9.7 mi)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

John Suh is a Radiation Oncologist in Cleveland, Ohio. Dr. Suh is highly rated in 35 conditions, according to our data. His top areas of expertise are Brain Tumor, Astrocytoma, Glioma, Glioblastoma, and Gamma Knife Radiosurgery. Dr. Suh is currently accepting new patients.

Expertise in
7
conditions
Dr. Daniel E. Spratt
Radiation Oncology
Expertise in
7
conditions
Dr. Daniel E. Spratt
Radiation Oncology

University Hospitals Medical Group Inc

11100 Euclid Ave, 
Cleveland, OH 
 (8.9 mi)
216-844-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Daniel Spratt is a Radiation Oncologist in Cleveland, Ohio. Dr. Spratt is highly rated in 7 conditions, according to our data. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Bone Tumor, Prostatectomy, and Orchiectomy. Dr. Spratt is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Weller's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 11 Advanced Conditions
View All 31 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile